MSH2 alterations were present in 32 patients overall, most commonly in the STS cohort (n=22), including nine patients with sarcoma NOS, three patients with undifferentiated pleomorphic sarcoma, two patients with leiomyosarcoma, two patients with rhabdomyosarcoma, one patient with pleomorphic liposarcoma, one patient with well-differentiated liposarcoma, one patient with liposarcoma NOS, one patient with solitary fibrous tumor, one patient with angiosarcoma, and one patient with alveolar soft part sarcoma. This evidence concerns the gene MSH2 and rhabdomyosarcoma.